基本情報
- CAS
33754-49-3- 標準SMILES
Cc1nn(C)c2c1C(c1ccccc1F)=NCC(=O)N2C.Cl- InChIKey
NJERAXSSDSHLGE-UHFFFAOYSA-N- 分子式
- C15H16ClFN4O
- 平均分子量
- 322.76 g/mol
- 単同位体質量
- 322.099667
概要
See also: Zolazepam (has active moiety); Tiletamine Hydrochloride; Zolazepam Hydrochloride (component of).
名称と識別子
- 優先名称
- Zolazepam Hydrochloride
- IUPAC
- 4-(2-fluorophenyl)-1,3,8-trimethyl-6H-pyrazolo[5,4-e][1,4]diazepin-7-one;hydrochloride
- 現地名
- ゾラゼパム·塩酸塩
- 英語名
- ZOLAZEPAM HYDROCHLORIDE (500 MG)
- 分子式
- C15H16ClFN4O
- 分子量
- 322.7651432
名称と別名
Zolazepam hydrochlorideZolazepam HCl33754-49-3CI-71645SJ093Q1NPyrazolo(3,4-e)(1,4)diazepin-7(1H)-one, 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethyl-, monohydrochlorideHydrochloride, ZolazepamRefChem:58788CI716251-668-74-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo[3,4-e][1,4]diazepin-7(1H)-one monohydrochloride4-(o-Fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo(3,4-e)(1,4)diazepin-7(1H)-one monohydrochloride
名称をさらに表示
ゾラゼパム塩酸塩ゾラゼパム·塩酸塩4-(2-フルオロフェニル)-6,8-ジヒドロ-1,3,8-トリメチルピラゾロ[3,4-e][1,4]ジアゼピン-7(1H)-オン·塩酸塩ゾラゼパム・塩酸塩4-(2-フルオロフェニル)-6,8-ジヒドロ-1,3,8-トリメチルピラゾロ[3,4-e][1,4]ジアゼピン-7(1H)-オン・塩酸塩ZOLAZEPAM HYDROCHLORIDE)ZOLAZEPAN HYDROCHLORIDEZOLAZEPAM HYDROCHLORIDE (500 MG)Zolazepam hydrochloride solutionZolazepam Hydrochloride (1724805)Pyrazolo3,4-e1,4diazepin-7(1H)-one, 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethyl-, monohydrochloride
物性
構造計算による物性
- 極性表面積
- 50.5 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 4
- 回転可能結合数
- 1
- 重原子数
- 22
- 形式電荷
- 0
- 複雑度
- 455
実験および物理化学的性質
Animal DrugsFDA approved animal drugs -> Active ingredient
物理化学的性質
- 貯蔵温度
- -20 °C · -20°C
- 溶解性
- DMSO (Slightly, Heated), Methanol (Slightly), Water (Slightly)
- 外見
- Solid
- 色
- White to Off-White
- 主な用途
- 医薬品（低分子化合物）
- InChI
- 1S/C15H15FN4O.ClH/c1-9-13-14(10-6-4-5-7-11(10)16)17-8-12(21)19(2)15(13)20(3)18-9;/h4-7H,8H2,1-3H3;1H
- InChIKey
- NJERAXSSDSHLGE-UHFFFAOYSA-N
- SMILES
- Fc1c(cccc1)C2=NCC(=O)N(c3[n](nc(c32)C)C)C.[Cl-].[H+]
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
危険有害性情報
Regulatory InformationZolazepam hydrochloride: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and CategoriesAcute Tox. 4 (100%)
安全データ
- wgk
- WGK 3
- ridadr
- 3249
- hs_code
- 2933996500
- hazard_class
- 6.1(b)
- packing_group
- III
- ストレージクラス
- 11 - Combustible Solids
化学と産業
薬理情報
MeSH Pharmacological Classification
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.
応用分野
使用Sedative-hypnotic.
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…